--- title: "MacroGenics (MGNX) stock listing, news and investor profile" url: "https://aibio.space/companies/macrogenics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MacroGenics, Inc. (NASDAQ: MGNX), United States. The directory classifies it as Pharmaceuticals: Major." --- MGNX MacroGenics, Inc. NASDAQ · United States # MacroGenics (MGNX) news Mergers · 2026-07-07 ## [MacroGenics completes sale of CDMO manufacturing business to Bora for $122.5 million](https://aibio.space/news/macrogenics-completes-sale-cdmo-manufacturing-business-bora-122-5/) Bora Pharmaceuticals and Bora Biologics USA paid $122.5 million, before transaction fees and expenses, for MacroGenics' GMP manufacturing operations. The sale closed effective June 30, 2026 and is subject to post-closing adjustments. ## Latest MacroGenics news 1. 2026-07-07 Mergers [MacroGenics completes sale of manufacturing operations to Bora for $122.5 million](https://aibio.space/news/macrogenics-completes-sale-manufacturing-operations-bora-122-5-million/) Bora Pharmaceuticals took over MacroGenics' Rockville manufacturing site and hired about 140 former employees. The $122.5 million price is before fees, and the 8-K says extra post-closing payments may not be earned or received. ## MacroGenics at a glance - **Ticker**: MGNX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $113.9 million ### Related companies - [Annovis Bio](https://aibio.space/companies/annovis-bio/) NYSE: ANVS - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) NASDAQ: CORT - [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AMEX: AEON - [Emmaus Life Sciences](https://aibio.space/companies/emmaus-life-sciences/) OTC: EMMA - [SIGA Technologies](https://aibio.space/companies/siga-technologies/) NASDAQ: SIGA - [Turn Therapeutics](https://aibio.space/companies/turn-therapeutics/) NASDAQ: TTRX - [MERA PHARMACEUTICALS INC](https://aibio.space/companies/mera-pharmaceuticals/) OTC: MRPI - [Ocular Therapeutix](https://aibio.space/companies/ocular-therapeutix/) NASDAQ: OCUL ### Also on NASDAQ - [Soligenix](https://aibio.space/companies/soligenix/) SNGX - [Oramed Pharmaceuticals](https://aibio.space/companies/oramed-pharmaceuticals/) ORMP - [Imunon](https://aibio.space/companies/imunon/) IMNN - [RadNet](https://aibio.space/companies/radnet/) RDNT - [Nyxoah SA](https://aibio.space/companies/nyxoah/) NYXH - [X4 Pharmaceuticals](https://aibio.space/companies/x4-pharmaceuticals/) XFOR ## What MacroGenics does MacroGenics, Inc. is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. It uses antibody-drug conjugates (ADCs) and multi-specific antibodies, which it calls DART and TRIDENT molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, and two ADCs, MGC026 and MGC028, targeting B7-H3 and ADAM9. An FDA partial clinical hold now stops new enrollment in the LINNET study of lorigerlimab in platinum-resistant ovarian cancer, following safety events in four patients. Existing study participants may continue to receive study drug. MacroGenics also operates a commercial-scale cGMP antibody manufacturing facility in Maryland and provides contract development and manufacturing services. Partnered work includes MGD024, a CD123 and CD3 bispecific developed with Gilead Sciences, Inc. The company says its collaborations have provided over $1.6 billion of non-dilutive funding since its inception in 2000. | Product or program | What it is | Stage | |---|---|---| | Lorigerlimab | Bispecific DART molecule targeting PD-1 and CTLA-4 | clinical; LINNET study on partial clinical hold | | MGC026 | B7-H3-targeting ADC with a novel TOP1i-based linker-payload | Phase 1 dose expansion, ongoing | | MGC028 | First-in-class ADAM9-targeting ADC | Phase 1 dose escalation | | MGC030 | Preclinical ADC targeting an undisclosed antigen | preclinical | | ZYNYZ (retifanlimab-dlwr) | Anti-PD-1 monoclonal antibody that the company out-licensed | approved by the FDA | | TZIELD (teplizumab-mzwv) | Anti-CD3 monoclonal antibody that the company sold to a partner | approved by the FDA | Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/mgnx-20251231.htm). ## MacroGenics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$149.5 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/) | [$150.0 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/) | | Research and development | [$147.2 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/) | [$177.2 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/) | | Net income (loss) | [-$74.6 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/) | [-$67.0 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/) | | Cash from operations | [-$81.0 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/) | [-$68.4 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/) | | Cash and equivalents | [$57.2 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000056/) | [$182.8 million](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $113.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about MacroGenics What is the ticker symbol of MacroGenics? MacroGenics, Inc. trades under the ticker MGNX on NASDAQ. Where is MacroGenics listed? MacroGenics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:M55; LS:A1W6ND; LSX:A1W6ND. What is the SEC CIK of MacroGenics? The SEC Central Index Key (CIK) for MacroGenics, Inc. is 1125345. Its filings are on SEC EDGAR. How many shares does MacroGenics have outstanding? 63,700,187 shares as of 2026-08-08, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is MacroGenics listed under? Our directory records MacroGenics, Inc. under United States. What does MacroGenics do? Our directory classifies MacroGenics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of MacroGenics? The ISIN recorded for MacroGenics, Inc. is US5560991094. Does aibio.space cover MacroGenics? aibio.space lists MacroGenics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is MacroGenics incorporated? SEC records list its state or country of incorporation as DE. What does MacroGenics develop? MacroGenics, Inc. is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. It uses antibody-drug conjugates (ADCs) and multi-specific antibodies, which it calls DART and TRIDENT molecules. What is Lorigerlimab from MacroGenics? Lorigerlimab: Bispecific DART molecule targeting PD-1 and CTLA-4 Stage: clinical; LINNET study on partial clinical hold. What is MGC026 from MacroGenics? MGC026: B7-H3-targeting ADC with a novel TOP1i-based linker-payload Stage: Phase 1 dose expansion, ongoing. What was MacroGenics's revenue last year? $149.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is MacroGenics profitable? MacroGenics, Inc. reported a net loss of $74.6 million for the fiscal year ended Dec 31, 2025, and used $81.0 million of cash in operations, per its annual report to the SEC. How much does MacroGenics spend on research and development? $147.2 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: MacroGenics Members talk about MacroGenics (MGNX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at MacroGenics, newest first. Each line links the filing it comes from. 1. 2026-07-07 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000045/exhibit99-1boraclosepressr.htm) 2. 2026-03-09 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000017/mgnx-20251231.htm) 3. 2025-03-20 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000042/mgnx-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MGNX on TradingView](https://www.tradingview.com/symbols/NASDAQ-MGNX/). ## SEC filings and registration - **SEC name**: Macrogenics Inc - **CIK**: 1125345 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: MGNX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 9704 MEDICAL CENTER DRIVE, Rockville, MD, 20850 - **Phone**: 301-251-5172 - **Shares outstanding**: 63,700,187 as of 2026-08-08 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000056/mgnx-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/mgnx-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000050/mgnx-20260723.htm) filed 2026-07-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000047/mgnx-20260701.htm) filed 2026-07-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000045/mgnx-20260630.htm) filed 2026-07-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000042/mgnx-20260519.htm) filed 2026-05-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000040/mgnx-20260513.htm) filed 2026-05-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000038/mgnx-20260331.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001125345), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details MacroGenics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MGNX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: MacroGenics, Inc. - **Ticker**: MGNX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US5560991094 - **Other listed symbols**: GETTEX:M55; LS:A1W6ND; LSX:A1W6ND - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MGNX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/macrogenics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MacroGenics (MGNX) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/macrogenics/